FACSIMILE TRANSMISSION

DATE:	November 14, 2002
TO:	Examiner Sonya N. Wright
FIRM:	USPTO
LOCATION:	Washington DC
NUMBER:	1-703-308-7922
FROM:	**Kenneth F. Mitchell Ph.D., Senior Patent Attorney**
LOCATION:	**AstraZeneca Pharmaceuticals LP, Wilmington**
NUMBER:	**FAX - 302-886-8221** **Phone - 302-886-7466**

Number of pages including cover sheet: **3**

If you have any questions or problems with this transmission, please call me at 302-886-7466.

COMMENTS:

UNOFFICIAL

AstraZeneca Docket No. **A2090-1P US**

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: **Loch III, et al.**
Application Number: **09/529,654**
Filed: **February 16, 2001**
For: **Novel Arylkyl Amines of Sprofuropyridines Useful in Therapy**
Group Art Unit: **1626**
Examiner: **Wright, Sonya N.**

Assistant Commissioner for Patents
Washington, DC 20231

INFORMAL SUBMISSION

Dear Examiner Wright:

I have discussed your concerns with the inventors of this application and Claim 1 amended with proviso indicated below would be acceptable.

1.(Amended) A compound of formula I,



I

wherein

NRR_1 is attached at the 5- or 6-position of the furopyridine ring;

R is hydrogen, C_1-C_4 alkyl, or COR_2;

R_1 is $(CH_2)_nAr$, $CH_2CH{=}CHAr$, or $CH_2C{\equiv}CAr$;

n is 0 to 3;

A is N or NO;

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or:

an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; any of which may optionally be substituted with one to two substitutents independently selected from: halogen, trifluoromethyl, or C_1-C_4 alkyl;

R_2 is hydrogen, C_1-C_4 alkyl; C_1-C_4 alkoxy; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH, OC_1–C_4 alkyl, CO_2R_5, –CN, –NO_2, –NR_3R_4, or –CF_3;

R_3, R_4 and R_5 are independently hydrogen; C_1-C_4 alkyl; or phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1–C_4 alkyl, C_2–C_4 alkenyl, C_2–C_4 alkynyl, OH, OC_1–C_4 alkyl,–CN; –NO_2, or –CF_3;

with the proviso that when R is hydrogen, R^1 is not phenyl or CH_2-phenyl;

or an enantiomer thereof, and pharmaceutically acceptable salts thereof.

Respectfully submitted,

Dated: November 14, 2002

By: K F Mitchell

Kenneth F. Mitchell, Ph.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466